Target validation for drug discovery in parasitic organisms.

Laurie K. Jackson, Margaret A. Phillips

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Parasite infections affect billions of humans world-wide, yet the current drugs available for the treatment of many parasitic diseases are either inadequate, or compromised by the development of resistance. Validation of a drug target is an important step in the development of new drugs. Target validation encompasses verifying that a target is primarily responsible for the therapeutic activity of a proven drug, or demonstrating the essential nature of a putative drug target in a parasite, and the capacity for selective inhibition of that target in vivo. Selective toxicity may be achieved by taking advantage of unique parasite biology or biochemistry, or by utilizing differences in metabolism or import. The essential nature of a target may be demonstrated by the correlation of the chemical or genetic reduction of target activity with the loss of parasite growth or virulence. Rescue experiments may demonstrate the single nature of a target. Ultimately, a target must be validated in vivo.

Original languageEnglish (US)
Pages (from-to)425-438
Number of pages14
JournalCurrent Topics in Medicinal Chemistry
Volume2
Issue number5
StatePublished - May 2002

Fingerprint

Drug Discovery
Parasitic Diseases
Parasites
Pharmaceutical Preparations
Biochemistry
Metabolism
Toxicity
Virulence
Growth
Experiments

ASJC Scopus subject areas

  • Medicine(all)
  • Chemistry(all)

Cite this

Target validation for drug discovery in parasitic organisms. / Jackson, Laurie K.; Phillips, Margaret A.

In: Current Topics in Medicinal Chemistry, Vol. 2, No. 5, 05.2002, p. 425-438.

Research output: Contribution to journalArticle

@article{a4da8b477a2c4fbab4003390befb91f7,
title = "Target validation for drug discovery in parasitic organisms.",
abstract = "Parasite infections affect billions of humans world-wide, yet the current drugs available for the treatment of many parasitic diseases are either inadequate, or compromised by the development of resistance. Validation of a drug target is an important step in the development of new drugs. Target validation encompasses verifying that a target is primarily responsible for the therapeutic activity of a proven drug, or demonstrating the essential nature of a putative drug target in a parasite, and the capacity for selective inhibition of that target in vivo. Selective toxicity may be achieved by taking advantage of unique parasite biology or biochemistry, or by utilizing differences in metabolism or import. The essential nature of a target may be demonstrated by the correlation of the chemical or genetic reduction of target activity with the loss of parasite growth or virulence. Rescue experiments may demonstrate the single nature of a target. Ultimately, a target must be validated in vivo.",
author = "Jackson, {Laurie K.} and Phillips, {Margaret A.}",
year = "2002",
month = "5",
language = "English (US)",
volume = "2",
pages = "425--438",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Target validation for drug discovery in parasitic organisms.

AU - Jackson, Laurie K.

AU - Phillips, Margaret A.

PY - 2002/5

Y1 - 2002/5

N2 - Parasite infections affect billions of humans world-wide, yet the current drugs available for the treatment of many parasitic diseases are either inadequate, or compromised by the development of resistance. Validation of a drug target is an important step in the development of new drugs. Target validation encompasses verifying that a target is primarily responsible for the therapeutic activity of a proven drug, or demonstrating the essential nature of a putative drug target in a parasite, and the capacity for selective inhibition of that target in vivo. Selective toxicity may be achieved by taking advantage of unique parasite biology or biochemistry, or by utilizing differences in metabolism or import. The essential nature of a target may be demonstrated by the correlation of the chemical or genetic reduction of target activity with the loss of parasite growth or virulence. Rescue experiments may demonstrate the single nature of a target. Ultimately, a target must be validated in vivo.

AB - Parasite infections affect billions of humans world-wide, yet the current drugs available for the treatment of many parasitic diseases are either inadequate, or compromised by the development of resistance. Validation of a drug target is an important step in the development of new drugs. Target validation encompasses verifying that a target is primarily responsible for the therapeutic activity of a proven drug, or demonstrating the essential nature of a putative drug target in a parasite, and the capacity for selective inhibition of that target in vivo. Selective toxicity may be achieved by taking advantage of unique parasite biology or biochemistry, or by utilizing differences in metabolism or import. The essential nature of a target may be demonstrated by the correlation of the chemical or genetic reduction of target activity with the loss of parasite growth or virulence. Rescue experiments may demonstrate the single nature of a target. Ultimately, a target must be validated in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0036580364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036580364&partnerID=8YFLogxK

M3 - Article

C2 - 11966465

AN - SCOPUS:0036580364

VL - 2

SP - 425

EP - 438

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 5

ER -